Investing in Cargo Therapeutics (CRGX) involves high risks typical of clinical-stage biotechnology enterprises, including the potential for clinical trial failures, regulatory approval delays, and intense competition in the oncology therapeutics sector. Because early-stage biopharmaceutical companies rely heavily on successful research outcomes and substantial capital to fund prolonged drug development cycles, any unfavorable safety data or setbacks in regulatory reviews can lead to sharp drops in share value or complete loss of invested capital.